Elicio Therapeutics, Inc.
NASDAQ:ELTXBiotechnology
-$0.89 today
- Market cap
- $51.48M
- Beta
- 1.14
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$2.21
Volume 0.41M
Average 0.34M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Elicio Therapeutics, Inc.
NASDAQ:ELTX
Intrinsic Alpha fair value
Locked
Current Price
$2.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
PepGen Inc. NASDAQ:PEPG | $217.19M | $3.14 | Not rated | -1.6 | -28.93% |
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | $192.32M | $10.38 | Not rated | -1.3 | -79.40% |
Nkarta, Inc. NASDAQ:NKTX | $190.31M | $2.66 | Not rated | -2.0 | -37.43% |
Molecular Partners AG NASDAQ:MOLN | $165.05M | $4.40 | Not rated | -2.0 | -38.90% |
Milestone Pharmaceuticals Inc. NASDAQ:MIST | $131.35M | $1.06 | Not rated | -2.5 | -80.24% |
Cardiff Oncology, Inc. NASDAQ:CRDF | $67.83M | $0.88 | Not rated | -1.8 | -55.37% |
Rani Therapeutics Holdings, Inc. NASDAQ:RANI | $57.48M | $0.88 | Not rated | -4.6 | -54.34% |
Actuate Therapeutics Inc NASDAQ:ACTU | $30.39M | $1.27 | Not rated | -2.3 | -64.27% |
Continue the stock analysis
Jump to another research area for this company.